-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Maintains Overweight on Vera Therapeutics, Lowers Price Target to $100

Benzinga·05/07/2025 14:22:51
Listen to the news
Cantor Fitzgerald analyst Pete Stavropoulos maintains Vera Therapeutics (NASDAQ:VERA) with a Overweight and lowers the price target from $107 to $100.